Memantine sustained release - Lyndra
Alternative Names: LYN-057; Memantine hydrochloride - Lyndra; Memantine modified release - LyndraLatest Information Update: 28 Oct 2021
At a glance
- Originator Lyndra
- Class Amines; Analgesics; Antidementias; Antiglaucomas; Antiparkinsonians; Antispastics; Antitussives; Eye disorder therapies; Nitrates; Nootropics; Organic bridged compounds; Small molecules; Vascular disorder therapies
- Mechanism of Action Nicotinic receptor antagonists; NMDA receptor antagonists; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Australia (PO, Capsule)
- 01 Feb 2019 Lyndra Therapeutics initiates enrolment in a phase I trial for Alzheimer’s disease in Australia before February 2019
- 15 Nov 2018 Positive pharmacokinetics and safety data from a phase-I trial in Healthy volunteers released by Lyndra Therapeutics